Galectin Therapeutics (GALT) Financial Statements

Compare

667 Followers

Galectin Therapeutics Financial Overview

Galectin Therapeutics's market cap is currently $180.54M. The company's EPS TTM is $; its P/E ratio is -8.32; Galectin Therapeutics is scheduled to report earnings on March 26, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 25	Dec 23	Dec 22	Mar 22	Mar 21
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -37.00K	$ -33.00K	$ -32.00K	$ -41.00K	$ -36.00K
Operating Income	$ -42.43M	$ -38.07M	$ -38.35M	$ -30.18M	$ -23.44M
EBITDA	$ -41.47M	$ -38.24M	$ -37.71M	$ -30.00M	$ -23.34M
Net Income	$ -47.05M	$ -41.07M	$ -38.78M	$ -30.53M	$ -23.46M
Balance Sheet
Cash & Short-Term Investments	$ 15.12M	$ 25.66M	$ 18.59M	$ 39.65M	$ 27.14M
Total Assets	$ 17.50M	$ 28.20M	$ 21.29M	$ 41.83M	$ 29.60M
Total Debt	$ 106.25M	$ 71.81M	$ 39.87M	$ 29.06M	$ 44.00K
Net Debt	$ 91.13M	$ 46.15M	$ 21.28M	$ -10.59M	$ -27.10M
Total Liabilities	$ 120.56M	$ 88.44M	$ 53.48M	$ 39.21M	$ 5.41M
Stockholders' Equity	$ -103.07M	$ -60.24M	$ -32.19M	$ 2.62M	$ 24.19M
Cash Flow
Free Cash Flow	$ -41.77M	$ -32.97M	$ -31.06M	$ -24.31M	$ -20.60M
Operating Cash Flow	$ -41.77M	$ -32.97M	$ -31.06M	$ -24.31M	$ -20.60M
Investing Cash Flow	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Financing Cash Flow	$ 31.23M	$ 40.03M	$ 10.00M	$ 36.81M	$ 263.00K

Currency in USD

Galectin Therapeutics Earnings and Revenue History

Income Statement >

Galectin Therapeutics Debt to Assets

Balance Sheet >

Galectin Therapeutics Cash Flow

Cash Flow >

Galectin Therapeutics Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >